Works matching IS 02683369 AND DT 2012 AND VI 47 AND IP 1

Results: 33

Carcinomatosis lymphangitis and pleurisy after allo-SCT in two patients with secondary leukemia after breast cancer.

Published in:

2012

By:

Chalayer, E;
Tavernier-Tardy, E;
Clavreul, G;
Bay, J-O;
Cornillon, J

Publication type:

Letter

CsA 2-h concentration correlates best with area under the concentration-time curve after allo-SCT compared with trough CsA.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 54, doi. 10.1038/bmt.2011.2

By:

Kong, D C M;
Shuttleworth, P;
Bailey, M;
Grigg, A

Publication type:

Article

Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 5, doi. 10.1038/bmt.2011.88

By:

Danylesko, I;
Shimoni, A;
Nagler, A

Publication type:

Article

Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 82, doi. 10.1038/bmt.2011.29

By:

Stover, D G;
Reddy, V K;
Shyr, Y;
Savani, B N;
Reddy, N

Publication type:

Article

Tear physiology in dry eye associated with chronic GVHD.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 115, doi. 10.1038/bmt.2011.36

By:

Khanal, S;
Tomlinson, A

Publication type:

Article

Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 15, doi. 10.1038/bmt.2011.32

By:

Chabannon, C;
Pamphilon, D;
Vermylen, C;
Gratwohl, A;
Niederwieser, D;
McGrath, E;
Lamers, C;
Lanza, F;
Slaper-Cortenbach, I;
Madrigal, A;
Apperley, J

Publication type:

Article

Prognostic value of response after upfront therapy for acute GVHD.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 125, doi. 10.1038/bmt.2011.41

By:

Saliba, R M;
Couriel, D R;
Giralt, S;
Rondon, G;
Okoroji, G-J;
Rashid, A;
Champlin, R E;
Alousi, A M

Publication type:

Article

Molecular remission of FLT3-ITD+ positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib.

Published in:

2012

By:

Krüger, W H;
Hirt, C;
Kiefer, T;
Neumann, T;
Busemann, C;
Dölken, G

Publication type:

Letter

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 18, doi. 10.1038/bmt.2011.9

By:

Douglas, K W;
Parker, A N;
Hayden, P J;
Rahemtulla, A;
D'Addio, A;
Lemoli, R M;
Rao, K;
Maris, M;
Pagliuca, A;
Uberti, J;
Scheid, C;
Noppeney, R;
Cook, G;
Bokhari, S W;
Worel, N;
Mikala, G;
Masszi, T;
Taylor, R;
Treisman, J

Publication type:

Article

Oral cavity care in patients after high-dose chemotherapy and stem cell transplantation: The East Forum EBMT Nurses Group standard of care.

Published in:

2012

By:

Bystricka, E;
Ghelase, R;
Gorican, I K S;
Mazur, E;
Vokurka, S

Publication type:

Letter

Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 33, doi. 10.1038/bmt.2011.39

By:

Jaing, T-H;
Hung, I-J;
Yang, C-P;
Chen, S-H;
Chung, H-T;
Tsay, P-K;
Wen, Y-C

Publication type:

Article

Severe pruritus and hypothermia as the primary manifestations of Human Herpes Virus-6 encephalitis after pediatric cord blood transplantation.

Published in:

2012

By:

Hudspeth, M;
Brown, Evangeline;
Ragucci, D;
Dixon, T;
Turner, R

Publication type:

Letter

Early allo-SCT for AML with a complex aberrant karyotype-results from a prospective pilot study.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 46, doi. 10.1038/bmt.2011.15

By:

Schmid, C;
Schleuning, M;
Tischer, J;
Holler, E;
Haude, K-H;
Braess, J;
Haferlach, C;
Baurmann, H;
Oruzio, D;
Hahn, J;
Spiekermann, K;
Schlimok, G;
Schwerdtfeger, R;
Buechner, T;
Hiddemann, W;
Kolb, H-J

Publication type:

Article

Allogeneic hematopoietic stem cell collection from a donor with end-stage renal disease.

Published in:

2012

By:

Ahmad, I;
Kiss, T;
Lachance, S;
Roy, J;
Cohen, S

Publication type:

Letter

The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 88, doi. 10.1038/bmt.2011.12

By:

Protheroe, R E;
Kirkland, K E;
Pearce, R M;
Kaminaris, K;
Bloor, A;
Potter, M N;
Nagra, S;
Gilleece, M H;
McQuaker, I G;
Jackson, G;
Cook, G;
Marks, D I

Publication type:

Article

In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 101, doi. 10.1038/bmt.2011.28

By:

Dominietto, A;
Tedone, E;
Soracco, M;
Bruno, B;
Raiola, A M;
Van Lint, M T;
Geroldi, S;
Lamparelli, T;
Galano, B;
Gualandi, F;
Frassoni, F;
Bacigalupo, A

Publication type:

Article

Secondary solid tumors after allogeneic hematopoietic SCT in Japan.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 95, doi. 10.1038/bmt.2011.23

By:

Yokota, A;
Ozawa, S;
Masanori, T;
Akiyama, H;
Ohshima, K;
Kanda, Y;
Takahashi, S;
Mori, T;
Nakaseko, C;
Onoda, M;
Kishi, K;
Doki, N;
Aotsuka, N;
Kanamori, H;
Maruta, A;
Sakamaki, H;
Okamoto, S

Publication type:

Article

The role of HLA-G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 120, doi. 10.1038/bmt.2011.40

By:

Chiusolo, P;
Bellesi, S;
Piccirillo, N;
Giammarco, S;
Marietti, S;
De Ritis, D;
Metafuni, E;
Stignani, M;
Baricordi, O R;
Sica, S;
Leone, G;
Rizzo, R

Publication type:

Article

A case of membranous nephropathy associated with chronic GVHD successfully treated with rituximab.

Published in:

2012

By:

Iguchi, E;
Minakata, T;
Tsudo, M

Publication type:

Letter

Prognostic impact of iron parameters in patients undergoing allo-SCT.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 60, doi. 10.1038/bmt.2011.13

By:

Bazuave, G N;
Buser, A;
Gerull, S;
Tichelli, A;
Stern, M

Publication type:

Article

Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD.

Published in:

2012

By:

Osumi, T;
Miharu, M;
Tanaka, R;
Du, W;
Takahashi, T;
Shimada, H

Publication type:

Letter

Successful allo-HSCT with a minimal myeloablative conditioning regimen in an adult patient with Fanconi's anemia.

Published in:

2012

By:

Maekawa, K;
Yoshimitsu, M;
Fujiwara, H;
Matsushita, K;
Kawada, H;
Hamada, H;
Suzuki, S;
Uozumi, K;
Ohtsuka, M;
Hanada, S;
Yabe, M;
Yabe, H;
Arima, N

Publication type:

Letter

Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 24, doi. 10.1038/bmt.2011.33

By:

Milone, G;
Poidomani, M;
Leotta, S;
Avola, G;
Camuglia, M G;
Privitera, A;
Consoli, C;
Mercurio, S;
Romeo, M A;
Di Marco, A;
Di Mercurio, S;
Spadaro, A;
Palumbo, G A;
Tedeschi, P

Publication type:

Article

Outcome of children requiring intensive care following haematopoietic SCT for primary immunodeficiency and other non-malignant disorders.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 40, doi. 10.1038/bmt.2011.26

By:

Cole, T S;
Johnstone, I C;
Pearce, M S;
Fulton, B;
Cant, A J;
Gennery, A R;
Slatter, M A

Publication type:

Article

Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 65, doi. 10.1038/bmt.2011.16

By:

Delioukina, M;
Zain, J;
Palmer, J M;
Tsai, N;
Thomas, S;
Forman, S

Publication type:

Article

Serum (1 → 3)-β-D-glucan levels (Fungitell assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement.

Published in:

2012

By:

Duffner, U;
Abdel-Mageed, A;
Dahl, K;
Fogg, G;
Hester, J

Publication type:

Letter

G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 73, doi. 10.1038/bmt.2011.22

By:

Su, Y-C;
Li, S-C;
Hsu, C-K;
Yu, C-C;
Lin, T-J;
Lee, C-Y;
Liao, H-F

Publication type:

Article

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.

Published in:

2012

By:

Awan, F T;
Osman, S;
Kochuparambil, S T;
Gibson, L;
Remick, S C;
Abraham, J;
Craig, M;
Jillella, A;
Hamadani, M

Publication type:

Letter

Encouraging results of preserving ovarian function after allo-HSCT with RIC.

Published in:

2012

By:

Shimizu, M;
Sawada, A;
Yamada, K;
Kondo, O;
Koyama-Sato, M;
Shimizu, S;
Komura, H;
Yasui, M;
Inoue, M;
Kawa, K

Publication type:

Letter

What we know and mostly do not know about bronchiolitis obliterans syndrome.

Published in:

2012

By:

Martin, P J;
Chien, J W

Publication type:

Editorial

Higher CD3+ and CD34+ cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 1, p. 107, doi. 10.1038/bmt.2011.3

By:

Gaziev, J;
Isgrò, A;
Marziali, M;
Daniele, N;
Gallucci, C;
Sodani, P;
Simone, M D;
Adorno, G;
Paciaroni, K;
Andreani, M;
Lanti, A;
Del Proposto, G;
Testi, M;
De Angelis, G;
Roveda, A;
Alfieri, C;
Saltarelli, F;
Lucarelli, G

Publication type:

Article

Intensive chemotherapy for a relapsed ALL patient who received living-donor lobar lung transplantation.

Published in:

2012

By:

Ishiyama, K;
Okumura, H;
Yamazaki, H;
Kondo, Y;
Waseda, Y;
Kotani, T;
Takami, A;
Nakao, S

Publication type:

Letter

Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.

Published in:

2012

By:

Alchalby, H;
Lioznov, M;
Fritzsche-Friedland, U;
Badbaran, A;
Zabelina, T;
Bacher, U;
Stübig, T;
Ayuk, F A;
Zander, A R;
Kröger, N

Publication type:

Letter

Works matching IS 02683369 AND DT 2012 AND VI 47 AND IP 1

Carcinomatosis lymphangitis and pleurisy after allo-SCT in two patients with secondary leukemia after breast cancer.

CsA 2-h concentration correlates best with area under the concentration-time curve after allo-SCT compared with trough CsA.

Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.

Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma.

Tear physiology in dry eye associated with chronic GVHD.

Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program.

Prognostic value of response after upfront therapy for acute GVHD.

Molecular remission of FLT3-ITD<sup>+</sup> positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib.

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.

Oral cavity care in patients after high-dose chemotherapy and stem cell transplantation: The East Forum EBMT Nurses Group standard of care.

Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients.

Severe pruritus and hypothermia as the primary manifestations of Human Herpes Virus-6 encephalitis after pediatric cord blood transplantation.

Early allo-SCT for AML with a complex aberrant karyotype-results from a prospective pilot study.

Allogeneic hematopoietic stem cell collection from a donor with end-stage renal disease.

The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study.

In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT.

Secondary solid tumors after allogeneic hematopoietic SCT in Japan.

The role of HLA-G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis.

A case of membranous nephropathy associated with chronic GVHD successfully treated with rituximab.

Prognostic impact of iron parameters in patients undergoing allo-SCT.

Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD.

Successful allo-HSCT with a minimal myeloablative conditioning regimen in an adult patient with Fanconi's anemia.

Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.

Outcome of children requiring intensive care following haematopoietic SCT for primary immunodeficiency and other non-malignant disorders.

Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.

Serum (1 → 3)-β-D-glucan levels (Fungitell assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement.

G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT.

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.

Encouraging results of preserving ovarian function after allo-HSCT with RIC.

What we know and mostly do not know about bronchiolitis obliterans syndrome.

Higher CD3<sup>+</sup> and CD34<sup>+</sup> cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia.

Intensive chemotherapy for a relapsed ALL patient who received living-donor lobar lung transplantation.

Circulating CD34<sup>+</sup> cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.